Atomwise
-
Artificial Intelligence, BioPharma
Drug-discovery firm nets $14.5M in Series A funding
X-37 leverages AI technology similar to facial recognition to figure out which small molecules can bind most effectively with targeted enzymes.
-
Novartis, Microsoft partner to use artificial intelligence in drug research
The partnership will enable researchers from the Swiss drugmaker to use AI to find insights hidden in large amounts of data while also finding new approaches to personalized medicine in certain diseases and the manufacture of cell and gene therapies.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Startups, Artificial Intelligence, BioPharma
Personalized cancer treatment startup Notable Labs nabs $40M Series B
Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company’s technology and growth of its commercial use cases.
-
Artificial Intelligence, BioPharma
Watson for Drug Discovery may be down, but AI in biopharma isn’t out
Last month, it was reported that IBM would stop selling Watson for Drug Discovery, but executives in the field of biopharma artificial intelligence say the field is still going strong.
-
Artificial Intelligence, BioPharma
Atomwise, Charles River Labs partner to provide AI services in drug discovery
The partnership with the Massachusetts-based CRO could yield up to $2.4 billion in royalties for Atomwise, if projects are successful.